Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma

A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the combination of vorinostat with bevacizumab and CPT-11 in recurrent glioblastoma. Vorinostat was combined with bevacizumab and CPT-11 and was escalated using a standard 3 + 3 design....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chinnaiyan, Prakash, Chowdhary, Sajeel, Potthast, Lisa, Prabhu, Antony, Tsai, Ya-Yu, Sarcar, Bhaswati, Kahali, Soumen, Brem, Steven, Yu, H. Michael, Rojiani, Amyn, Murtagh, Ryan, Pan, Edward
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2012
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3246000/
https://ncbi.nlm.nih.gov/pubmed/22028388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor187
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados